Hypertension is a perplexing multiorgan disease involving renal primary pathology and enhanced angiotensin II vascular reactivity. Here, we report that a novel form of a local Ca 2ϩ signaling in arterial smooth muscle is linked to the development of angiotensin II-induced hypertension. Long openings and reopenings of L-type Ca 2ϩ channels in arterial myocytes produce stuttering persistent Ca 2ϩ sparklets that increase Ca 2ϩ influx and vascular tone. These stuttering persistent Ca 2ϩ sparklets arise from the molecular interactions between the L-type Ca 2ϩ channel and protein kinase C␣ at only a few subsarcolemmal regions in resistance arteries. We have identified AKAP150 as the key protein, which targets protein kinase C␣ to the L-type Ca 2ϩ channels and thereby enables its regulatory function. Accordingly, AKAP150 knockout mice (AKAP150 Ϫ/Ϫ ) were found to lack persistent Ca 2ϩ sparklets and have lower arterial wall intracellular calcium ([Ca 2ϩ ] i ) and decreased myogenic tone. Furthermore, AKAP150 Ϫ/Ϫ mice were hypotensive and did not develop angiotensin II-induced hypertension. We conclude that local control of L-type Ca 2ϩ channel function is regulated by AKAP150-targeted protein kinase C␣ signaling, which controls stuttering persistent Ca 2ϩ influx, vascular tone, and blood pressure under physiological conditions and underlies angiotensin II-dependent hypertension. (Circ Res. 2008;102:e1-e11.) Key Words: L-type Ca 2ϩ channels Ⅲ protein kinase C Ⅲ myogenic tone Ⅲ total internal reflection fluorescence microscopy Original
H ypertension is a major risk factor for the development of stroke, coronary artery disease, heart failure, and renal disease. 1 Although the principal cause of hypertension is renal, vascular dysfunction is critical, 2 and the increased arterial tone associated with hypertension contributes to the development of the pathology. This is highlighted by recent studies indicating that the endogenous vasoconstrictor angiotensin II is a likely contributor to vascular dysfunction in human 3, 4 and model [5] [6] [7] [8] [9] [10] [11] [12] [13] hypertension. Accordingly, the angiotensin II signaling system is the target for two major classes of pharmacological agents (angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists) that are widely used clinically for the treatment of hypertension in humans. At present, however, the molecular mechanisms by which angiotensin II signaling causes vascular dysfunction and contributes to hypertension are unclear. Here, we address that conundrum and provide a novel and surprising answer.
Increased L-type Ca 2ϩ channel activity in arterial myocytes is thought to be necessary for the development of vascular dysfunction during hypertension. 9,11,14 -17 Ca 2ϩ entry into arterial myocytes occurs through the opening of a single or a cluster of L-type Ca 2ϩ channels. These channels produce local elevations in intracellular calcium ([Ca 2ϩ ] i ) called "Ca 2ϩ sparklets". 18 -20 The activation of multiple Ca 2ϩ sparklets increases global [Ca 2ϩ ] i , which activates myosin light chain, resulting in contraction.
Identification of sarcolemmal L-type Cav1.2 channels as the molecular entity underlying Ca 2ϩ sparklets in arterial myocytes is based on multiple pharmacological, biophysical, and molecular biological studies. First, Ca 2ϩ sparklets are eliminated by dihydropyridine antagonists and enhanced by dihydropyridine agonists and are insensitive to intracellular store depletion with thapsigargin. 18 -20 Furthermore, unlike Ca 2ϩ release events from intracellular stores, Ca 2ϩ sparklets are rapidly eliminated by the removal of extracellular Ca 2ϩ . 18, 19, 21 Second, unlike Ca 2ϩ release events from intracellular Ca 2ϩ stores, Ca 2ϩ sparklets are associated with an inward L-type Ca 2ϩ current. 18, 20 Consistent with this, Ca 2ϩ sparklets have similar voltage dependencies of amplitude and activity as Cav1.2 channels. 18 -21 Third, Ca 2ϩ sparklets in tsA-201 cells expressing Cav1.2 channels reproduce all the basic features (eg, pharmacology, amplitude of quantal event, voltage dependence, activity, etc) of native Ca 2ϩ sparklets. 19, 21 Finally, arterial myocytes expressing dihydropyridine-insensitive Cav1.2 channels produce dihydropyridine-insensitive Ca 2ϩ sparklets. 21 A striking feature of Ca 2ϩ sparklet activity in vascular smooth muscle is that it is modal. 18, 19 In low activity mode, rare stochastic openings of solitary L-type Ca 2ϩ channels produce limited Ca 2ϩ influx. In contrast, discrete clusters of L-type Ca 2ϩ channels that colocalized with protein kinase (PK) C␣ operate in a sustained, high-activity mode, resulting in substantial Ca 2ϩ influx (ie, "stuttering persistent Ca 2ϩ sparklets"). 18 -20 Thus, in principle, vasoconstrictors such as angiotensin II, which activate PKC, could increase myogenic tone and blood pressure by specifically stimulating local persistent Ca 2ϩ sparklet activity.
Although produced by Ͻ1% of the functional L-type Ca 2ϩ channels located in an area representing Ͻ1% of the total surface membrane, persistent Ca 2ϩ sparklets are a major contributor to Ca 2ϩ influx and [Ca 2ϩ ] i in arterial myocytes. 18 These findings are significant because they raise the intriguing possibility that the targeting of PKC␣ to the sarcolemma of arterial myocytes is critical for local persistent Ca 2ϩ sparklet activity and hence for the regulation of arterial wall [Ca 2ϩ ] i , myogenic tone, blood pressure, and the development of hypertension. Thus, delocalization of PKC␣ from the sarcolemma could be a rational strategy for the selective elimination of persistent Ca 2ϩ sparklets and the treatment of hypertension. However, the targeting mechanism directing PKC␣ to the sarcolemma is unknown.
Here, we examined the role of the scaffolding protein AKAP150 in the regulation of Ca 2ϩ sparklet activity, arterial wall [Ca 2ϩ ] i , myogenic tone, blood pressure, and angiotensin II-dependent hypertension. We focused on AKAP150 because it binds to PKC␣, [22] [23] [24] PKA, calcineurin, and L-type Ca 2ϩ channels, 25 making this scaffolding protein a potential key regulator of persistent Ca 2ϩ sparklet activity and thus vascular function and blood pressure. Our data indicate that AKAP150 is required for local targeting of PKC␣ to the sarcolemma of arterial myocytes. Furthermore, we found that AKAP150 was necessary for PKC␣-dependent persistent Ca 2ϩ sparklet activity, but not for rare, stochastic L-type Ca 2ϩ channel activity. This suggests that AKAP150/PKC␣ signaling does not increase L-type Ca 2ϩ channel activity globally. Rather, this signaling complex increases Ca 2ϩ influx locally by selectively coercing small clusters of L-type Ca 2ϩ channels to operate in a persistent gating mode that create sites of sustained Ca 2ϩ influx. We also found that AKAP150 Ϫ/Ϫ arteries had lower [Ca 2ϩ ] i and developed less myogenic tone than wild-type (WT) arteries. Consistent with this, AKAP150 Ϫ/Ϫ mice were hypotensive under control conditions and, unlike WT, did not develop hypertension during chronic angiotensin II infusion. We propose that stuttering persistent Ca 2ϩ sparklet activity, myogenic tone, and blood pressure are regulated locally by the subcellular targeting of PKC␣ by AKAP150.
Materials and Methods

Isolation of Arterial Myocytes
WT (C57BL/6J), AKAP150 knockout 25 (AKAP150 Ϫ/Ϫ , genetic background C57BL/6J), and mice expressing an AKAP150 lacking its PKA binding site (the carboxyl-terminal 36 amino acids [AKAP150⌬36]) were euthanized with a lethal dose of sodium pentobarbital (250 mg/kg IP), as approved by the University of Washington Institutional Animal Care and Use Committee. Myocytes were dissociated from mesenteric and cerebral arteries using standard enzymatic techniques described elsewhere. 26 After dissociation, cells were maintained in a nominally Ca 2ϩ -free Ringer's solution until used. Thapsigargin (1 mol/L) was included in all solutions used to record Ca 2ϩ sparklets to eliminate Ca 2ϩ release from intracellular stores during experimentation.
RT-PCR and Western Blots
Total RNA was isolated from WT or AKAP150 Ϫ/Ϫ of Ϸ60 arterial myocytes ( Figure 1A Figure 1 . AKAP150 is expressed in arterial myocytes and is located in foci that colocalize with PKC␣ near the sarcolemma of arterial myocytes. A, Image of an agarose gel showing AKAP150, PKC␣, and ␤-actin mRNA amplicons. mRNA was obtained from WT arterial myocytes. B, Representative confocal images of WT arterial myocytes labeled with Alexa 594 -conjugated WGA (Bi) to identify the sarcolemma and a PKC␣specific antibody (Bii) or WGA (Bv) and AKAP150-specific antibody (Bvi). Bii shows a surface plot of PKC␣-associated fluorescence in a typical WT cell. The images in Biii and Bvii were generated by merging the images Bi and Bii or Bv and Bvi, respectively. Biv and Bviii are surface plots of PKC␣-associated fluorescence (green wire frame) and WGAassociated fluorescence (solid, red surface plot) in the region within the white box in panels Biii and Bvii. C, Confocal images of a representative WT arterial myocyte labeled with AKAP150specific (left) and PKC␣-specific (center) antibodies. The image to the right was produced by merging the AKAP150 and PKC␣ images. The graph plots a frequency histogram of the PKC␣ and AKAP150 fluorescence intensity pixel pairing in the membrane region in the images described above. The pixel pairing used for this plot had Pearson's and Mander's coefficients of ϩ0.84 and ϩ0.92, respectively. manufacturer. We designed primers specific for PKC␣ (GenBank accession No. NM_011101; sense nucleotides 1120 to 1140 and antisense nucleotides 1312 to 1331; ampliconϭ211 bp) and AKAP150 (GenBank accession XM_915706; sense nucleotides 58 to 80 and antisense nucleotides 444 to 464, ampliconϭ406 bp). The L-type Cav1.2 subunit (GenBank accession No. NM_012517) was detected with a set of commercial primers (SuperArray) that amplify a sequence between nucleotides 6548 to 6567 (ampliconϭ164 bp). We used ␤-actin (GenBank accession V01217; sense nucleotides 2384 to 2404 and antisense nucleotides 3071 to 3091; ampliconϭ496 bp) transcript levels as an internal control for these experiments. ␤-Actin primers amplify a region between exons 4 and 6 such that genomic contamination within the RNA preparation is identified by the presence of a 708-bp band in addition to the 496-bp band. Reverse transcription and amplification was performed using the OneStep RT-PCR kit from Qiagen following the instructions of the manufacturer. To do this, we used an Eppendorf Thermal Cycler running the following program: 35 cycles at 94°C for 1 minute; 56°C for 1 minute; 72°C for 1 minute each cycle, with a final extension step of 72°C for 10 minutes. The amplicons were visualized using 2% agarose gel electrophoresis. Relative abundance of the transcripts in AKAP150 Ϫ/Ϫ mice was normalized to the expression of the WT transcripts. An optical density analysis was used to quantify amplicons.
Western blot analysis was performed using a previously described method 9 with minor modifications. Briefly, WT or AKAP150 Ϫ/Ϫ mesentery and cerebral arteries were harvested and homogenized in ice-cold NP-40 buffer (1% Triton X-100, 0.15 mol/L NaCl, 0.01 mol/L sodium phosphate). These homogenates were then centrifuged at 10 000g for 10 minutes (4°C), and the supernatant was recovered. Protein concentration was determined using a Bio-Rad BCA kit. Total protein extracts were separated on 4% to 15% SDS-polyacrylamide gels (Bio-Rad) and transferred to nitrocellulose membranes. The membranes were blocked in Tris-buffered saline with Tween (TBST) (25 mmol/L Tris-HCL, pH7.3, 0.15 mol/L NaCl, 0.1% Tween-20) containing 5% milk and probed with primary antibody (mouse monoclonal anti-PKC␣ antibody from Abcam; goat polyclonal anti-AKAP150 antibody from Santa Cruz Biotechnology, Santa Cruz, Calif; mouse monoclonal anti-Actin antibody from Chemicon) diluted in blocking buffer (1:250) for 1 hour. After extensive wash in TBST, membranes were probed with donkey anti-mouse or anti-goat IgG (Santa Cruz Biotechnology) and then washed in TBST. Horseradish peroxidase bound to immunoblot was visualized with enhanced chemiluminescence (ECL) (Amersham Biosciences) and Amersham ECL film. Protein was quantified using densitometry.
Immunofluorescence
To label the sarcolemma of arterial myocytes, we used an Alexa 594 -conjugated wheat germ agglutinin (WGA), which binds to sialic acid residues of sarcolemmal glycoproteins. Briefly, isolated arterial myocytes were incubated in 10 g/mL WGA for 1 hour before being plated on laminin-coated coverslips and allowed to settle for 2 hours. After plating, but before fixation and permeabilization (see below), cells were washed in PBS to remove any excess of WGA. Immunofluorescence labeling of dispersed myocytes was performed as described previously 20 using a monoclonal antibody specific for PKC␣ (Abcam, Cambridge, Mass), a polyclonal antibody specific for AKAP150 (Santa Cruz Biotechnology), and/or an Alexa 594 -conjugated WGA to label the surface membrane (Molecular Probes). The secondary antibodies were an Alexa Fluor 488 -conjugated rabbit anti-mouse (5 mg/mL), Alexa Fluor 488conjugated donkey anti-goat, or an Alexa Fluor 568 -conjugated donkey anti-goat (5 mg/mL) from Molecular Probes. Cells were imaged (512ϫ512 pixel images) using our confocal system coupled with a Nikon ϫ60 oil immersion lens (NAϭ1.4) and a zoom of 3.5 (pixel sizeϭ0.1 m). The point spread function of our confocal system showed that it has a lateral and axial resolution of 0.30 m and 0.80 m, respectively. Images were collected at multiple optical planes (z-axis step sizeϭ1 m).
We tested the specificity of our labeling by performing a negative control experiment in which the primary antibodies were substituted with PBS. PKC␣-or AKAP150-associated fluorescence was undetectable under these conditions (data not show). Double-labeling experiments with anti-PKC␣ or anti-AKAP150 were used for colocalization analysis on paired of images (at multiple z-axis planes) using NIH ImageJ software with the colocalization analysis plug-in. Pearson's correlation and Mander's overlap coefficients 27 were calculated from those images. These analyses quantify the correlation or overlap between PKC␣ and AKAP150 signals, ranging from 0 for no colocalization to 1 for complete colocalization. Fluorescence was quantified by measuring the intensity of pixels above a set threshold defined as the mean nonspecific fluorescence intensity within cells (ie, cell background, secondary antibody only) plus 3 times its SD in WT and AKAP150 Ϫ/Ϫ arterial myocytes. The location of PKC␣ and AKAP150 clusters with respect to the membrane was determined by measuring the shortest distance between the epicenter of these clusters and the center of the WGA fluorescence at multiple focal planes.
We obtained the ratio of near-membrane to cytosol PKC␣ using an approach similar to the one used by Khalil et al. 28 Briefly, for each cell, pixel intensities within a 1-m section from the edge of the cell (which includes the cell membrane) were determined. Next, a spatially equivalent section of cytosol was selected and the intensity of each pixel averaged. From these measurements, we determined the ratio of PKC␣ fluorescence at the different locations and used this as an indicator of PKC␣ translocation and activity. 28 The delimitation of the cell was obtained using two independent approaches. (1) In some experiments we used a threshold analysis in which the boundary of the cell (ie, surface membrane) was detected as having background fluorescence intensity that was larger than the mean plus 3 SDs of the image intensity outside the cell. (2) We also used WGA-associated fluorescence to determine the location of the surface membrane. Note that WGA-associated fluorescence over-lapped with the edge of the cell, as determined using the threshold analysis described above, indicating that either of these 2 approaches can be used to estimate the location of the sarcolemma of arterial myocytes.
Patch-Clamp Electrophysiology
We used the conventional whole-cell patch-clamp technique to control membrane voltage and record L-type Ca 2ϩ currents using an Axopatch 200B amplifier. During experiments, cells were continuously superfused with a solution containing (mmol/L): 120 NЈmethyl-D-glucamine, 5 CsCl, 1 MgCl 2 , 10 glucose, 10 HEPES, and 20 CaCl 2 adjusted to pH 7.4. Pipettes were filled with a solution composed of (mmol/L) 87 Cs-aspartate, 20 CsCl, 1 MgCl 2 , 5 MgATP, 10 HEPES, 10 EGTA, and adjusted to pH 7.2 with CsOH. For Ca 2ϩ sparklets experiments, 0.2 mmol/L fluo-5F was added to the pipette solution. A voltage error of 10 mV resulting from liquid junction potential of these solutions was corrected for. Whole-cell L-type Ca 2ϩ currents (I Ca ) were recorded using a step depolarization of 200 ms from the holding potential of Ϫ70 mV to ϩ30 mV. I Ca was measured as the difference between the peak and the sustained current at the end of the 200-ms pulse. Because murine cerebral arterial smooth muscle cells do not express functional T-type Ca 2ϩ channels and are insensitive to dihydropyridine agonists and antagonists, 29,30 the voltage-gated, time-dependent currents evoked under these experimental conditions (ie, Na ϩ and K ϩ free external solution) have been shown to be produced by L-type Ca 2ϩ channels. Currents were sampled at 20 kHz and low pass-filtered at 2 kHz.
[Ca 2؉ ] i and Myogenic Tone in Pressurized Arteries
Arterial wall [Ca 2ϩ ] i was imaged using a Radiance 2100 confocal system (Cambridge, Mass) coupled to a Nikon TE2000S inverted microscope equipped with a Nikon 20X (NAϭ0.75) lens. Small mesenteric arteries (types II and III) from WT and AKAP150 Ϫ/Ϫ mice were removed and cleaned in normal Ringer's solution. Isolated arteries were cannulated and mounted in a close-workingdistance arteriograph. The endothelium of the artery was disrupted by passing air bubbles through their lumen. Endothelial damage was confirmed by the absence of a dilator response to acetylcholine (5 mol/L) after the development of tone (data not shown). The arteriograph was placed on the stage of the inverted microscope and the artery was extraluminally perfused (3 to 6 mL/min) at 37°C with a bicarbonate-based physiological saline solution composed of (mmol/L): 119 NaCl, 4.7 KCl, 24 NaHCO 3 , 1.2 KH 2 PO 4 , 1.6 CaCl 2 , 1.2 MgSO 4 , and 11 glucose with the pH set to 7.4 by bubbling with a gas mixture of O 2 (95%) and CO 2 (5%). After equilibration (20 minutes), intravascular pressure was increased to 80 mm Hg for 20 minutes. Arteries were loaded with the Ca 2ϩ indicator fluo-4 as described elsewhere. 20 All fluorescence recordings were corrected for background (eg, autofluorescence, etc) before analysis. Arterial viability was tested by raising external K ϩ to 60 mmol/L. Arteries that failed to contract robustly in response to high [K ϩ ] were discarded.
Pressurized artery diameter measurements from WT and AKAP150 Ϫ/Ϫ mice were obtained from small mesenteric arterial segments 1 to 2 mm in length. These arterial segments were cannulated and mounted in a close-working-distance arteriograph. The arteriograph was placed on the stage of the inverted microscope (Nikon TE 2000S), and the artery segment was extraluminally perfused (3 to 6 mL/min) at 37°C with the same bicarbonate solution described above. After equilibration at 0 mm Hg for 20 minutes, steady-state changes in intravascular pressure were achieved by elevating or lowering an attached reservoir and monitored using a pressure transducer. Internal diameters were measured from live video images with the length-calibrated edge-detection function of an IonOptix imaging software at a sampling rate of 1 Hz. Myogenic tone was assessed by subjecting the vessels to a series of pressure steps between 40 and 100 mm Hg. Spontaneous myogenic tone was allowed to develop at each step. Experiments were terminated by the addition of 10 mol/L diltiazem in nominally Ca 2ϩ -free bicarbonatebase solution, after which the pressure response curve was repeated to obtain the passive diameter of the artery. Myogenic tone was calculated as the percentage difference in active diameter versus passive diameter at each pressure. To determine angiotensin IIinduced constriction, arteries were pressurized to 80 mm Hg and superfused with a solution containing 100 nmol/L angiotensin II. Induced constriction was defined as the percentage decrease in internal diameter after the application of the contractile stimuli versus passive diameter. Again, arterial viability was tested by raising external K ϩ to 60 mmol/L. Arteries that failed to contract robustly in response to high [K ϩ ] were discarded.
Analysis of fluorescence signals proceeded as follows. Background fluorescence (ie, arterial and nonarterial autofluorescence) was subtracted from the total fluorescence signal of fluo-4/5Floaded arteries and cells. Fluo-4 and fluo-5F fluorescence signals were then converted to Ca 2ϩ concentration units using the "F max " equation 31 :
as described in detail previously. 19, 20 Briefly, F is fluorescence, F max is the fluorescence intensity of fluo-4/5F or rhod-2 in the presence of saturating free Ca 2ϩ , K d is the dissociation constant of (fluo-5Fϭ1280 nmol/L; fluo-4ϭ800 nmol/L), and R f (fluo-5Fϭ286; fluo-4ϭ150) is the F max /F min ratio of the indicator. F min is the fluorescence intensity of the indicator in a solution in which the Ca 2ϩ concentration is 0. K d and R f values were determined in vitro using standard methods and are similar to those reported by others. 32 F max was determined at the end of each experiment by exposing cells or arteries to the Ca 2ϩ ionophore ionomycin (10 mol/L) and 20 mmol/L external Ca 2ϩ . We used the F max method developed by Maravall et al 31 to convert fluorescence signals from a nonratiometric Ca 2ϩ indicator (fluo-5F or fluo-4) to calcium concentration units for multiple reasons. First, the F max method has been thoroughly tested and, with indicators like fluo-4/5F, found to give [Ca 2ϩ ] i estimates that are similar to those obtained with ratiometric indicators. Second, we met all the conditions required to apply this method (ie, negligible rates of photobleaching; we used an indicator with a known dissociation constant that has a high affinity for Ca 2ϩ , as well as a high dynamic range, and we determined F max for each cell). Third, unlike the pseudoratio method, 33 the F max method does not require one to assume resting levels of [Ca 2ϩ ] i . This last point represents a major advantage of the F max method.
Total Internal Reflection Fluorescence Microscopy
Ca 2ϩ sparklets were recorded in patch-clamped (whole-cell configuration) arterial myocytes (from cerebral and mesenteric arteries) as previously described. 18 -21 Cells were held at the hyperpolarized potential of Ϫ70 mV to increase the driving for Ca 2ϩ entry (ie, relatively large Ca 2ϩ sparklet amplitude) and thus allow the recording of quantal Ca 2ϩ sparklets. Briefly, we used a through-the-lens total internal reflection fluorescence (TIRF) microscope built around an inverted Olympus IX-70 microscope equipped with an Olympus PlanApo (ϫ60; NAϭ1.45) oil immersion lens and an Andor iXON CCD camera (South Windsor, Conn). To monitor [Ca 2ϩ ] i , cells were loaded with the calcium indicator fluo-5F as described above. As in previous studies, 18 -21 we used the relatively slow Ca 2ϩ buffer EGTA (on-rate Ϸ100-fold slower than fluo-5F) to enhance the "TIRF effect" and further restrict the fluorescence of fluo-5 to near the site of calcium entry (Ϸ1 m). 34 Note that a similar strategy has been used to record Ca 2ϩ release sites in ventricular myocytes using confocal microscopy. 35, 36 In this scenario, calcium entering the cell preferentially interacts with the faster fluo-5F, producing fluorescence, but then quickly (on average Ϸ2 ms) 34 binds to the more abundant and nonfluorescent EGTA. Thus, in our TIRF experiments in which fluo-5F and EGTA are used, intracellular calcium signals are limited to the submembrane space near the mouth of L-type Ca 2ϩ channels. For a more detailed discussion of these issues, see Amberg et al. 20 Excitation of fluo-5F was achieved with the 488-nm line of an argon laser (Dynamic Lasers, Salt Lake City, Utah). Images were acquired at 100 to 300 Hz. As before, 18, 19 we determined the activity of Ca 2ϩ sparklets by calculating the nP s of each Ca 2ϩ sparklet site, where n is the number of quantal levels and P s is the probability that a quantal Ca 2ϩ sparklet event is active. As previously reported, all data sets were submitted to a normality test to determine whether they had a Gaussian distribution. Because Ca 2ϩ sparklet activity has a bimodal distribution, Ca 2ϩ sparklet sites were grouped into 3 categories: silent (by default has an nP s of 0), low (nP s between 0 and 0.2), and high (nP s higher than 0.2). Comparison of the entire nP s data set was performed using nonparametric data analyses (Mann-Whitney test). Comparison between low and high nP s groups was performed using parametric data analyses (2-tailed Student's t test). A detailed description of this analysis can be found in Navedo et al. 19 
Telemetry Blood Pressure Recordings
Blood pressure was monitored in conscious adult WT and AKAP150 Ϫ/Ϫ mice before and after angiotensin II treatment using a telemetry system (Data Science International). Briefly, mice were anesthetized with isoflurane. A ventral midline incision from the lower mandible to the sternum was made to isolate the left common carotid. Two lengths of 7-0 silk sutures were threaded beneath the vessel for retraction and ligation. The artery was permanently ligated at the level of the bifurcation between the interior and exterior carotid. The second suture was used to occlude blood flow temporally and allow insertion of the catheter. A 25-gauge syringe needle was used to make an incision in the artery through which the tip of the catheter was inserted. The catheter was advanced to the thoracic aorta and tied in place with the suture. A subcutaneous pocket was then made to place the transmitter body. After placement of the transmitter body the incision was closed with 5-0 sutures.
Blood pressure was recorded continuously and stored in the hard drive of a personal computer running Dataquest software (Data Science International). Control blood pressure measurements began 7 days after surgery to allow animals to recover. After this recovery period, blood pressures were recorded for 3 days before the saline or angiotensin II osmotic minipump was implanted. Angiotensin II was delivered at a rate of 800 ng/kg per minute. 9, 11, 37, 38 Preparation and implantation of these pumps was performed as described elsewhere. 9, 11 Blood pressure recordings continued for up to 7 days after pump implantation.
Chemicals and Statistics
All chemicals were from Sigma-Aldrich (St Louis, Mo) unless stated otherwise. Gö6976 was from Calbiochem. Normally distributed data are presented as meansϮSEM. Two-sample comparisons were made using a Student's t test. Nonparametric statistical analyses (Mann-Whitney test) were used for nonnormally distributed data. Probability values less than 0.05 were considered significant. Asterisks used in the figures indicate a significant difference between groups.
Results
Investigation of the links between vascular Ca 2ϩ signaling and blood pressure regulation under control conditions and following angiotensin II elevation requires the examination of L-type Ca 2ϩ channels and related proteins in vascular smooth muscle. To investigate the molecular links between the L-type Ca 2ϩ channel and PKC␣, we examined a candidate protein: AKAP150. This is a member of a family of proteins 39 known to be scaffolding molecules that facilitate local signaling between and among an assembly of proteins, often enabling the organization of a macromolecular signaling complex.
AKAP150 Targets PKC␣ to the Sarcolemma of Arterial Myocytes
RT-PCR was used to determine what, if any, AKAP150 may be present in arterial smooth muscle myocytes. We found that
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AKAP150 transcript was expressed in arterial myocytes ( Figure 1A) . As a control, we also detected PKC␣ and ␤-actin transcripts in these cells. This identification, however, raised the question of whether AKAP150 may be interacting with PKC␣ as a functional entity, as hypothesized. An immunofluorescence approach was used to determine the spatial distribution of AKAP150 and PKC␣ protein in WT arterial myocytes. As shown in the representative cell in Figure 1B , we observed clear AKAP150-and PKC␣-associated fluorescence in WT arterial myocytes. For these experiments, an Alexa 594-conjugated WGA (see Figure 1Bi and 1Bv), which binds sialic acid residues in glycoproteins, was used to label the sarcolemma of arterial myocytes. PKC␣ fluorescence was observed throughout the cell and in discrete foci near (Ͻ1 m) WGA fluorescence in arterial myocytes (Figure 1Bii through 1Biv). Interestingly, AKAP150 fluorescence was confined to specific regions of the cell near the WGA fluorescence (Figure 1Biv through 1Bviii) . A relatively small number of AKAP150 and PKC␣ clusters were observed per cell (rangeϭ1 to 7 per cell, nϭ15), each with an area of 0.54Ϯ0.09 m 2 . AKAP150 fluorescence was never observed in AKAP150 Ϫ/Ϫ myocytes (data not shown). These data suggest that AKAP150 and PKC␣ form clusters near the sarcolemma of arterial myocytes.
An immunofluorescence approach was also used to determine whether AKAP150 and PKC␣ colocalize in WT arterial myocytes. As illustrated in Figure 1C , we observed colocalization of AKAP150 (red) and PKC␣ (green) clusters near the boundaries of the cell (see Materials and Methods above for details about the spatial resolution of our microscope). Quantitative colocalization is shown in the plot of PKC␣ fluorescence versus that of AKAP150 on a pixel-by-pixel basis. The statistical significance of the colocalization is supported by Mander's overlap and Pearson correlation coefficients of ϩ0.92 and ϩ0.84, respectively. Together with the transcript and immunofluorescence data above, these data demonstrate that AKAP150 transcript and protein are expressed in arterial myocytes and that this scaffolding protein colocalizes with PKC␣ in small subsarcolemmal clusters in these cells.
The colocalization of AKAP150 and PKC␣ raised the question of a linkage between the 2 proteins and whether or not AKAP150 is required for PKC␣ targeting to specific regions of the sarcolemma. If so, then PKC␣ should not be found in puncta along the sarcolemma in the absence of AKAP150. Indeed, and unlike WT cells (Figure 2Ai through 2Aiii), clusters of PKC␣ were never observed in AKAP150 Ϫ/Ϫ myocytes (Figure 2Aiv through 2Avi) . Importantly, however, PKC␣ was still present in the knockout cells, but was diffusely distributed throughout the cytoplasm (Figure 2Aiv through 2Avi ). Consistent with this observation, we found that the overall abundance of PKC␣ transcript ( Figure  2B ) and protein ( Figure 2C ) was similar in WT and AKAP150 Ϫ/Ϫ arteries. These data support the hypothesis that AKAP150 is required for local PKC␣ targeting into the sarcolemma of arterial myocytes.
AKAP150 and PKC Increase Basal L-Type Ca 2؉ Channel Currents in Arterial Myocytes
Next, we examined I Ca in WT and AKAP150 Ϫ/Ϫ myocytes (Figure 3 ). As demonstrated by others (eg, Cobine et al 40 and Amberg et al 20 ) , inhibition of PKC with Gö69766 (200 nmol/L) decreased I Ca in WT arterial myocytes, suggesting that basal PKC activity increases L-type Ca 2ϩ channel function in these cells ( Figure 3A) . Conversely, application of the PKC activator phorbol 12,13-dibutyrate (PDBu) (200 nmol/L) increased I Ca nearly 2.3-fold in WT cells (nϭ4; PϽ0.05).
A testable prediction from the immunofluorescence experiments described above is that I Ca should be smaller in AKAP150 Ϫ/Ϫ than in WT myocytes because of loss of sarcolemmal localized PKC␣. Consistent with this hypothesis, we found that I Ca was Ϸ63% smaller in AKAP150 Ϫ/Ϫ (nϭ14) than in WT myocytes ( Figure 3A; nϭ9, PϽ0.05) . In contrast to WT, application of Gö69766 or PDBu did not change I Ca in AKAP150 Ϫ/Ϫ myocytes. Note also that the basal I Ca in AKAP150 Ϫ/Ϫ cells was reduced to a level comparable to WT cells treated with a PKC inhibitor (nϭ4, PϾ0.05). Consistent with this, Cav1.2 (and PKC␣; see above), the predominant L-type Ca 2ϩ channel in arterial myocytes, 21, 30, 41 transcript expression was similar (nϭ4; PϾ0.05) in WT and AKAP150 Ϫ/Ϫ arterial smooth muscle ( Figure 3B ). This suggests that differences in the expression of this pore-forming subunit do not account for differential I Ca in WT and AKAP150 Ϫ/Ϫ myocytes. Together with the electrophysiological, immunofluorescence, and molecular biological (eg, PKC␣ expression) data described above, these data support the hypothesis that delocalization of PKC is responsible for the decrease in I Ca in AKAP150 Ϫ/Ϫ myocytes.
AKAP150 Is Required for Persistent Ca 2؉ Sparklet Activity in Arterial Myocytes
We imaged the elementary Ca 2ϩ influx events underlying I Ca in arterial myocytes: Ca 2ϩ sparklets. This is critical because Ca 2ϩ sparklet activity varies within the sarcolemma of arterial myocytes, 19 which cannot be detected with the conventional whole-cell patch-clamp approaches used above. As described in the introduction, the majority of L-type Ca 2ϩ channels in these cells operate in low open probability mode that causes small, sporadic elevations in [Ca 2ϩ ] i (ie, low-activity Ca 2ϩ sparklets). In contrast, discrete clusters of L-type Ca 2ϩ channels associated with PKC␣ operate in a sustained, highactivity mode that result in substantial Ca 2ϩ influx (ie, stuttering persistent Ca 2ϩ sparklets). 18 -20 Regional variations in PKC␣ activity have been suggested to underlie this novel Ca 2ϩ signaling modality. However, the mechanisms underlying heterogeneous PKC␣ distribution and Ca 2ϩ sparklet activity in these cells are unclear. One potential mechanism suggested by the data described above is that AKAP150 targets PKC␣ to subsarcolemmal microdomains, where it can modulate the function of nearby L-type Ca 2ϩ channels and induce stuttering persistent Ca 2ϩ sparklet activity.
One testable prediction of this hypothesis is that persistent Ca 2ϩ sparklet activity should either be lower or absent in AKAP150 Ϫ/Ϫ compared with WT arterial myocytes. Consistent with this, Ca 2ϩ sparklet activity (nP s ; Ϫ70 mV) was e6 Circulation Research February 1, 2008 lower in AKAP150 Ϫ/Ϫ than in WT cells (Figure 4 ). Indeed, Ca 2ϩ sparklets were rarely observed in AKAP150 Ϫ/Ϫ myocytes ( Figure 4A and 4C) . The lower level of Ca 2ϩ sparklet activity in AKAP150 Ϫ/Ϫ myocytes was attributable to an absence of high activity, persistent Ca 2ϩ sparklet sites (nP s Ͼ0.2) ( Figure 4B and 4D) as the mean nP s value of low activity Ca 2ϩ sparklets was similar in WT (0.11Ϯ0.05; nϭ55) and AKAP150 Ϫ/Ϫ myocytes (0.10Ϯ0.01; nϭ8; Pϭ0.38). Activation of PKC␣ increases persistent Ca 2ϩ sparklet activity in arterial myocytes. 19 Thus, we examined the effects of direct and receptor-mediated PKC activation with PDBu (200 nmol/L) and angiotensin II (100 nmol/L) on Ca 2ϩ sparklet activity in WT and AKAP150 Ϫ/Ϫ myocytes. We found that application of these vasoconstrictors evoked persistent Ca 2ϩ sparklet activity in WT but not in AKAP150 Ϫ/Ϫ myocytes ( Figure 4A through 4D; see also Movie 1 in the online data supplement).
In addition to PKC␣, AKAP150 also binds calcineurin and PKA. 23 In WT myocytes, inhibition of calcineurin with cyclosporin A increased Ca 2ϩ sparklet activity by Ϸ3.1-fold 19 but was without effect in AKAP150 Ϫ/Ϫ arterial myocytes (nϭ5; data not shown). We also investigated the possibility that PKA binding to AKAP150 was participating in the regulation of PKC-dependent persistent Ca 2ϩ sparklet activity. To do this, we examined Ca 2ϩ sparklet activity in WT cells and in arterial myocytes from a mouse expressing an AKAP150 lacking its PKA binding site (the carboxyl-terminal 36 amino acids; referred to as AKAP150⌬36) before and after application of PDBu (see Figure 5 ). Unlike AKAP150 Ϫ/Ϫ cells, WT levels of low and high nP s Ca 2ϩ sparklets were observed in AKAP150⌬36 myocytes under control conditions. Furthermore, application of PDBu (200 nmol/L) or cyclosporin A (500 nmol/L; Figure 5 ) increased persistent Ca 2ϩ sparklet activity to the same extent in AKAP150⌬36 (nϭ5) and WT myocytes (nϭ5, PϾ0.05) but not in AKAP150 Ϫ/Ϫ myocytes. Together with the AKAP150 Ϫ/Ϫ data above, these findings demonstrate that association of PKC␣, but not PKA, with AKAP150 is required for localized persistent Ca 2ϩ sparklet activity in arterial myocytes.
Loss of AKAP150 Decreases Arterial Wall [Ca 2؉ ] i and Tone
Next, we compared arterial wall [Ca 2ϩ ] i in pressurized (80 mm Hg) arterial segments from WT and AKAP150 Ϫ/Ϫ arterial segments ( Figure 6A ). We found that under control conditions, [Ca 2ϩ ] i was lower in AKAP150 Ϫ/Ϫ (nϭ5) than in WT (nϭ5, PϽ0.05) arteries. Transient application of angiotensin II (100 nmol/L) increased [Ca 2ϩ ] i in AKAP150 Ϫ/Ϫ arteries slightly, but to a significantly smaller extent, than in WT arteries ( Figure 6B ; PϽ0.05). Note that in the presence of the L-type Ca 2ϩ channel blocker nifedipine (1 mol/L) arterial wall [Ca 2ϩ ] i was similar in WT and AKAP150 Ϫ/Ϫ arteries (Ϸ100 nmol/L; PϾ0.05), as expected if the L-type Ca 2ϩ channel were ultimately responsible for the effect.
To examine the physiological consequences of reduced I Ca , Ca 2ϩ sparklet activity, and [Ca 2ϩ ] i in AKAP150 Ϫ/Ϫ smooth muscle, we evaluated the effect of pressure on the diameter of WT and AKAP150 Ϫ/Ϫ arteries ( Figure 6C and 6D) . Elevation of intravascular pressure constricts small resistance arteries. 42 Consistent with our I Ca , Ca 2ϩ sparklet, and [Ca 2ϩ ] i data, AKAP150 Ϫ/Ϫ arteries (nϭ5) were significantly less constricted than WT arteries at all intravascular pressures examined ( Figure 6D; nϭ5; PϽ0.05 ). Furthermore, angiotensin II evoked a smaller contraction in AKAP150 Ϫ/Ϫ than in WT arteries ( Figure 6E ). These findings suggest that AKAP150 is required for basal and angiotensin II-induced changes in arterial [Ca 2ϩ ] i and is an important component of myogenic tone. Furthermore, our results are consistent with the hypothesis that physiological modulation of vascular tone by angiotensin II depends on the modulation of stuttering persistent Ca 2ϩ sparklets.
In addition to increasing [Ca 2ϩ ] i , PKC␣ enhances smooth muscle contraction by increasing the sensitivity of contractile filaments to [Ca 2ϩ ] i . 43, 44 AKAP150 could thus be necessary for PKC␣-induced sensitization of myofilaments during angiotensin II signaling. To provide insight into this fundamental issue, we calculated the ratio of the mean arterial tone to [Ca 2ϩ ] i during angiotensin II treatment in WT and AKAP150 Ϫ/Ϫ arteries (see Figure 6 ). We found that, on average, the ratio of arterial tone to [Ca 2ϩ ] i was similar in AKAP150 Ϫ/Ϫ (29% tone per 216 nmol/Lϭ 0.13% tone per nmol/L) and WT (50% tone per 369 nmol/Lϭ 0.14% tone per nmol/L) arteries. This analysis suggests that the amount of myogenic tone developed per unit of [Ca 2ϩ ] i was similar in WT and AKAP150 Ϫ/Ϫ arteries during angiotensin II signaling. Thus, although targeting of PKC␣ to the sarcolemma by AKAP150 is required for activation of persistent Ca 2ϩ sparklet activity, it is not essential for the modulation of the Ca 2ϩ sensitivity of contractile filaments during angiotensin II signaling.
AKAP150 Is Required for Angiotensin II-Induced Hypertension
Chronic activation of angiotensin II signaling contributes to the development of hypertension in mice and humans. 3, 4, 9, 11 To examine the role of AKAP150/PKC␣-dependent, persistent Ca 2ϩ sparklets in this process, we examined blood pressure in AKAP150 Ϫ/Ϫ and WT mice infused with saline (control) or angiotensin II ( Figure 7A ). Mean arterial pressure (MAP) was significantly lower in AKAP150 Ϫ/Ϫ (102Ϯ2 mm Hg, nϭ9) than in WT (116Ϯ3 mm Hg, nϭ6; PϽ0.05) mice infused with saline. As expected, angiotensin II infusion significantly increased MAP in WT to 149Ϯ3 mm Hg (PϽ0.05). Interestingly, MAP in angiotensin II-infused AKAP150 Ϫ/Ϫ mice (120Ϯ3 mm Hg) was similar (PϾ0.05) to that of normotensive WT mice infused with saline. Thus, although angiotensin II induced a small increase in blood pressure in AKAP150 Ϫ/Ϫ mice (⌬MAPϭ14Ϯ4 mm Hg), this response was Ϸ2.4-fold lower than in WT mice (⌬MAPϭ33Ϯ4 mm Hg; PϽ0.05) and equalized MAP in AKAP150 Ϫ/Ϫ infused with angiotensin II and normotensive, saline-infused WT mice (PϾ0.05). These data demonstrate that AKAP150 regulates basal blood pressure and plays a critical role in the development of angiotensin II-dependent hypertension.
Discussion
The findings reported here suggest that AKAP150 is required for stuttering persistent Ca 2ϩ sparklets and for the regulation of myogenic tone, blood pressure, and the development of angiotensin II-induced hypertension. Indeed, our data support a new model of Ca 2ϩ signaling in vascular smooth muscle in which AKAP150 targets PKC␣ to relatively small regions of the sarcolemma of arterial myocytes. Local targeting of PKC␣ by AKAP150 is responsible for persistent Ca 2ϩ sparklet activity, but not for rare, stochastic L-type Ca 2ϩ channel openings (ie, low-activity Ca 2ϩ sparklets). Our data suggest that AKAP150 is required for PKC␣-dependent persistent Ca 2ϩ sparklets and thus regulates arterial [Ca 2ϩ ] i , myogenic tone, and blood pressure. Furthermore, AKAP150 is necessary for the development of angiotensin II-induced hypertension. Thus, we propose that AKAP150 regulates myogenic tone, blood pressure, and the development of angiotensin II-induced hypertension, at least in part, by local control of PKC␣-dependent stuttering persistent Ca 2ϩ influx. The implications of these findings are discussed below. The evidence linking PKC␣ to persistent Ca 2ϩ sparklet activity is numerous. First, pharmacological inhibition of PKC␣ eliminates persistent Ca 2ϩ sparklet activity. 18 -20 Second, PKC␣-null (PKC␣ Ϫ/Ϫ ) arterial myocytes, which presumably express AKAP150 and other associated proteins, have low-activity, but not high-activity, persistent Ca 2ϩ sparklet activity. 19, 20 Third, activation of PKC increases persistent Ca 2ϩ sparklet activity. Fourth, expression of PKC␣ and Cav1.2 channels in tsA-201 cells is sufficient to produce persistent Ca 2ϩ sparklets. Ca 2ϩ sparklets were never observed in control (ie, nontransfected) tsA-201 cells. 19, 21 These findings provide compelling support for the hypothesis that PKC␣ and L-type Ca 2ϩ channel expression is necessary for basal and evoked stuttering persistent Ca 2ϩ sparklet activity in arterial myocytes and raise an important question: What are the mechanisms leading to local PKC␣-dependent persistent Ca 2ϩ sparklet activity? Examination of our data provides insight into this important issue. L-type Ca 2ϩ channels are expressed throughout the surface sarcolemma of smooth muscle cells. 18, 45 By contrast, in these cells, PKC␣ is found in small clusters near the sarcolemma of WT, but not in AKAP150 Ϫ/Ϫ , myocytes. Note, however, that PKC␣ transcript and protein expression was similar in WT and AKAP150 Ϫ/Ϫ arteries. Yet AKAP150 Ϫ/Ϫ myocytes, as with PKC␣ Ϫ/Ϫ myocytes 19 (see above), do not have persistent Ca 2ϩ sparklet activity, suggesting that PKC␣ expression alone is insufficient to induce persistent Ca 2ϩ sparklet activity in arterial myocytes. Rather, these data give credence to the view that targeting of PKC␣ by AKAP150 is crucial for the local control of stuttering persistent Ca 2ϩ sparklet activity in arterial myocytes.
Although our TIRF data provide compelling support to the hypothesis that Ca 2ϩ channel activity varies regionally within arterial myocytes, analysis of our immunofluorescence images provides further support for this concept. On average, the surface area of an arterial myocyte is Ϸ1000 m 2 . 18 We found that there are Ϸ7 AKAP150/PKC␣ clusters of Ϸ0.5 m 2 per cell (see Results section above). Accordingly, these clusters would account for only Ϸ0.3% (3.5 m 2 / 1000 m 2 ϫ100) of the entire sarcolemma. This analysis suggests that a relatively small fraction of the sarcolemma of arterial myocytes participates in AKAP150/PKC␣-mediated persistent Ca 2ϩ sparklet signaling, arterial function and thus blood pressure regulation.
In WT myocytes, activation of PKC␣ increases Ca 2ϩ influx by activating persistent Ca 2ϩ sparklet activity. 18, 19 However, AKAP150 Ϫ/Ϫ myocytes did not have persistent Ca 2ϩ sparklet activity and consequently had lower arterial [Ca 2ϩ ] i , tone, and response during angiotensin II signaling. Importantly, AKAP150 Ϫ/Ϫ mice did not develop angiotensin II-induced hypertension even though total PKC␣ expression is similar in WT and AKAP150 Ϫ/Ϫ arteries. On the basis of these findings, we suggest that PKC␣ targeting to specific foci in the sarcolemma by AKAP150 is necessary for persistent Ca 2ϩ sparklet activity in arterial myocytes and may contribute to the development of hypertension.
Elimination of persistent Ca 2ϩ sparklet activity per se would decrease arterial [Ca 2ϩ ] i and hence tone and blood pressure in AKAP150 Ϫ/Ϫ mice. However, it is important to note that it is possible that other AKAP150-dependent mechanisms, in combination with the loss of persistent Ca 2ϩ sparklets, also contribute to lower myogenic tone and blood pressure in these mice. For example, our data clearly indicate that angiotensin II increases Ca 2ϩ sparklet activity (ie, Ca 2ϩ influx) in WT arterial myocytes, presumably through the activation of PKC␣, with no changes in membrane potential (ie, in a voltage-clamped myocytes). However, in vivo activation of angiotensin II/PKC signaling has also been shown to inhibit voltage-gated, delayed-rectifier K ϩ chan- nels 46 and large conductance, Ca 2ϩ -activated K ϩ channels, 47, 48 which would lead to arterial smooth muscle depolarization. In addition, as demonstrated by Amberg et al, 20 membrane depolarization increases low-and high-activity persistent Ca 2ϩ sparklets in arterial myocytes. Consistent with this, 2 recent studies have suggested that PKC activity plays an important role in the regulation of membrane potential, Ca 2ϩ influx via L-type Ca 2ϩ channels, and the development of myogenic tone in coronary 40 and cerebral arteries. 49 Thus, in vivo, increased angiotensin II/PKC signaling could increase Ca 2ϩ sparklet activity by voltage-dependent and voltageindependent mechanisms.
AKAP150 binds PKC␣ and calcineurin but also PKA. 23 Activation of PKA causes vasodilation, 50 at least in part, by decreasing arterial smooth muscle [Ca 2ϩ ] i . Accordingly, loss of AKAP150, which would presumably eliminate targeting of PKA to the sarcolemma, could potentially lead to increased [Ca 2ϩ ] i , vasoconstriction, and blood pressure. However, Ca 2ϩ sparklet activity, I Ca , [Ca 2ϩ ] i , and blood pressure were lower in AKAP150 Ϫ/Ϫ than in WT mice. How could these seemingly contradictory findings be reconciled? One intriguing possibility is that the primary role of AKAP150 is to target PKC␣, not PKA, near L-type Ca 2ϩ channels in arterial myocytes. Consistent with this, Ca 2ϩ sparklet activity was similar in the AKAP150⌬36 mutant, which does not bind PKA, and WT myocytes. Furthermore, we found that activation of PKA with forskolin did not increase Ca 2ϩ sparklet activity in WT arterial myocytes. Thus, an AKAP other than AKAP150 may be the predominant anchor for PKA to the sarcolemma of arterial myocytes. Alternatively, PKA activity could be relatively low under basal conditions and during angiotensin II signaling, thus providing little opposition to the actions of PKC on Ca 2ϩ influx in arterial myocytes.
To conclude, our data indicate that AKAP150 plays a crucial role in the regulation of vascular function ( Figure 7D ). By targeting PKC␣, not PKA, and presumably calcineurin to specific sarcolemmal microdomains near L-type Ca 2ϩ channels, AKAP150 coordinates the formation of a signaling module that controls Ca 2ϩ influx, [Ca 2ϩ ] i , arterial tone, and hence blood pressure under physiological and pathophysiological conditions. Figure 7 . AKAP150 is required for angiotensin II-induced hypertension. A, Representative pressure waveforms of conscious WT and AKAP150 Ϫ/Ϫ mice before and after angiotensin II administration (right). B, Bar plot of MAP in WT (nϭ6) and AKAP150 Ϫ/Ϫ (nϭ9) mice infused with saline (control) or angiotensin II. MAP was similar in normotensive, saline-infused WT mice and AKAP150 Ϫ/Ϫ angiotensin II-infused mice (PϾ0.05). Angiotensin II-infused WT and AKAP150 Ϫ/Ϫ mice had MAPs of 149Ϯ3 mm Hg (nϭ5) and 120Ϯ3 mm Hg (nϭ8), respectively. *PϽ0.05 (2-tailed Student's t test). C, Proposed mechanism by which subcellular targeting of PKC␣ and calcineurin by AKAP150 control local stuttering persistent Ca 2ϩ sparklets. Under physiological conditions, low activity and stuttering persistent Ca 2ϩ sparklets contribute to arterial [Ca 2ϩ ] i and hence to the development of myogenic tone and the regulation of blood pressure. Increased angiotensin II signaling activates stuttering persistent Ca 2ϩ sparklets signals in arterial myocytes via AKAP150/PKC␣ signaling. This increases arterial [Ca 2ϩ ] i and myogenic tone and contributes to hypertension. 
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